613
Participants
Start Date
March 31, 2004
Primary Completion Date
October 31, 2005
Study Completion Date
October 31, 2005
Xarelto (Rivaroxaban, BAY59-7939)
10 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
Xarelto (Rivaroxaban, BAY59-7939)
20 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
Xarelto (Rivaroxaban, BAY59-7939)
30 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
Xarelto (Rivaroxaban, BAY59-7939)
40 mg od main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
Enoxaparin/Vitamin K-Antagonist
Enoxaparin/Vitamin K-Antagonist main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84). Enoxaparin was to be administered 1mg/kg bid sc for about 5-7 days. It was to be discontinued when INR was within the therapeutic range 2-3 for 2 consecutive days
Lima
Auckland
Vienna
Budapest
Vienna
Sydney
Duffel
Leuven
Bern
Melbourne
Melbourne
Melbourne
Basel
Debrecen
Adelaide
Adelaide
Perth
Lucerne
Szentes
Somerset West
Cape Town
Pécs
Christchurch
Graz
Zurich
Bloemfontein
Prague
Berlin
Berlin
Prague
Girona
Olot
Afula
Rozzano
Milan
Milan
Varese
Kladno
Madrid
Madrid
Piacenza
Pilsen
Haifa
Paderborn
Padua
San Cristóbal de La Laguna
Bologna
Reggio Emilia
Kfar Saba
Valencia
Bergisch Gladbach
Holon
Tel Aviv
Darmstadt
Mannheim
Heidelberg
Karlsbad
Ashkelon
München
Palermo
Jerusalem
São Paulo
São Paulo
Vancouver
Greater Sudbury
Hamilton
Hamilton
North Bay
Oshawa
Ottawa
Toronto
Windsor
Montreal
Montreal
Barranquilla
Bogotá
Medellín
Brno
Ostrava
Prague
Dresden
Perugia
's-Hertogenbosch
Arnhem
Dirksland
Enschede
Leidschendam
Rotterdam
The Hague
Auckland
Lima
Lima Cercado
Bialystok
Bytom
Gdansk
Katowice
Lublin
Olsztyn
Poznan
Warsaw
Pretoria
Pretoria
Pretoria
Badalona
Barcelona
Gothenburg
Gothenburg
Halmstad
Jönköping
Lund
Lead Sponsor
Bayer
INDUSTRY